Balaji S Srinivasan an Indian origin American, who is a successful Silicon Valley based entrepreneur and CEO of a bitcoin startup.

Srinivasan is being considered for Donald Trump administration’s pick to lead the Federal Drug Administration (FDA) after he met Donald Trump.

Srinivasan met Donald Trump at the Trump towers in New York on the 12th of January, but no official announcement has been made yet.

Sean Spicer, who is the incoming White House Press Secretary has confirmed that Srinivasan is being considered for the position of head FDA.

FDA is the important federal agency for drug and pharma industry.

Spicer also said that Jim O’Neil, who is the managing director of Mithril Capital Management is also being considered for the position in the FDA.

Balaji Srinivasan is currently serving as the CEO and co-founder of 21.Co and is also a partner in the Andreessen Horowitz. Srinivasan had also won the FDA approval as a genomics entrepreneurial.

According to Srinivasan’s Linkedin profile “ He is broadly interested in new technology, which a particular focus on ‘real world’ application’s digital bits interface with physical atoms and substantive problems, such as quantified self (healthcare), MOOCs/edtech (education), Bitcoin (finance), drones, and 3D printing."

Srinivasan has also served as a lecturer in the Departments of Statistics and Computer Science at the Stanford University.

Srinivasan described himself as a computer scientist, investor, entrepreneur and academic on his website. He was the CTO and Co-founder of Counsyl, which is a genomics startup that began in a Stanford dorm room, which now tests 4 % of all American births.

Srinivasan stepped back from an executive role in November 2012 after working for ten years in genomics and five years at Counsyl to work on other areas of technology.

According to the media reports Srinivasan is closely associated with Peter Thiel, who is a Silicon Valley venture capitalist and co-founder of Paypal.

AMandeep